Product Pathways - Growth Factors/Cytokines
Human His6Interleukin-25/IL-17E (hHis6IL-25) #12337
|12337LC||50 µg ( With Carrier )||￥6,860.00 现货查询||购买询价|
|12337LF||50 µg ( Carrier Free )||￥6,860.00 现货查询||购买询价|
|12337SC||10 µg ( With Carrier )||￥2,321.00 现货查询||购买询价|
|12337SF||10 µg ( Carrier Free )||￥2,321.00 现货查询||购买询价|
|12337||carrier free & custom formulation / quantity||email request|
Species cross-reactivity is determined by western blot.
Source / Purification
Recombinant human His6IL-25 (hHis6IL-25) Tyr33-Gly177 (Accession #NP_073626) was expressed in human 293 cells at Cell Signaling Technology.重组人His6IL-25 (hHis6IL-25) Tyr33-Gly177 (Accession #NP_073626) 通过Cell Signaling Technology公司的人源293细胞表达。
Recombinant N-terminally His6-tagged hIL-25 has a calculated MW of 19,318. DTT-reduced protein migrates as a 26-32 kDa polypeptide. The nonreduced cystine-linked homodimer migrates as a 40-46 kDa protein. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino terminus of recombinant hHis6IL-25 was verified by amino acid sequencing.
重组的hIL-25蛋白在N-末端有His6标签，其分子量据推算为19,318 Da。DTT还原蛋白迁移率接近26-32kDa 的多肽。未还原的胱氨酸相连的同源二聚体迁移蛋白大约40-46 kDa。其在SDS-PAGE胶中的低迁移性和多态性与糖基化有关。重组hHis6IL-6蛋白的N-末端序列通过测序得到。
>97% as determined by SDS-PAGE of 6 μg reduced (+) and nonreduced (-) recombinant hHis6IL-25. 30% migrates as monomer under nonreducing conditions. All lots are greater than 97% pure.
The bioactivity of recombinant hHis6IL-25 was determined by its ability to induce IL-5 production from TSLP-primed PBMC in the presence of IL-2. The ED50 of each lot is between 5-15 pg/ml.
重组人His6IL-25的生物活性通过对存在IL-2的TSLP预处理的PBMC 诱导产生IL-5的能力来确定。每个样品的ED50范围在5-15 pg/ml。
The purity of recombinant hHis6IL-25 was determined by SDS-PAGE of 6 µg reduced (+) and nonreduced (-) recombinant hHis6IL-25 and staining overnight with Coomassie Blue.通过SDS-PAGE纯化重组hHis6IL-25，方法是加入6 µg 诱导 (+)和未诱导的 (-) 重组hHis6IL-25，考马斯亮蓝染色过夜。
IL-5 production from human PBMC costimulated with IL-2 and increasing concentrations of hHis6IL-25 was assessed. PBMC were treated with TSLP (100 ng/ml, 24 hr) and then costimulated with IL-2 (10 ng/ml) and increasing concentrations of hHis6IL-25. After 72 hr, cell supernatants were harvested and assayed for IL-5 by ELISA and the OD450 was determined.IL-5是人源PBMC细胞中通过使用IL-2与浓度递增的hHis6IL-25共刺激后产生的。PBMC细胞使用TSLP (100 ng/ml, 24 小时)处理，接着使用IL-2 (10 ng/ml)和浓度递增的hHis6IL-25共刺激。72小时后，收集细胞上清，并且通过ELISA和OD450分析IL-5。
Less than 0.01 ng endotoxin/1 μg hHis6IL-25.
With carrier: Lyophilized from a 0.22 μm filtered solution of hHis6IL-25 in 20 mM Tris, pH 7.2 containing 150 mM NaCl and 20 μg BSA per 1 μg hHis6IL-25. Carrier free: Lyophilized from a 0.22 μm filtered solution of hHis6IL-25 in 20 mM Tris, pH 7.2 containing 150 mM NaCl.
有载体：每微克hHis6IL-25溶解在包含 20 μg BSA和150 mM NaCl的20 mM Tris （pH 7.2）溶液中，并通过 0.22 μm 滤膜过滤后冻干。
无载体：每微克hHis6IL-25溶解在包含 150 mM NaCl的20 mM Tris （pH 7.2）溶液中，并通过 0.22 μm 滤膜过滤后冻干。
IL-25, also known as IL-17E, is a member of the IL-17 superfamily of cytokines. IL-25 is expressed in epithelial cells, CD4+ T cells, mast cells, and eosinophils (1). Many cell types are responsive to IL-25, including T cells, macrophages, and epithelial cells (1). The receptor for IL-25 consists of a heterodimer of IL-17RA and IL-17RB (1,2). IL-25 promotes Th2 type immune responses by induction of IL-5, IL-4, and IL-13 and may contribute to allergic inflammation and asthma (1-3). IL-25 has also been shown in research to promote Th9 cell activation and induces apoptosis in breast cancer cells (4,5).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
用户评论 --- 共 0 条